Previously recorded as Mind Medicine, Inc. (to 2026)
Nine patents currently held, every record listed here
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2041. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2041
Next term end
7
Patent families
When these terms end
Each bar runs from grant to computed term end. 2022 to 2043.
US 11,532,396
System and Method for Patient Monitoring of Gastrointestinal Function Using Automated Stool Classifications
Mar 26, 2041
US 12,527,786
IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
no later than Aug 17, 2042
US 12,521,385
LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
no later than Aug 17, 2042
US 12,036,220
LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
Aug 17, 2042
US 11,896,670
Synthesis Routes to Access Mdma Prodrugs by Using Controlled and Non-Controlled Intermediates
Aug 23, 2042
202620302034203820422043
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
17 pending applications: term is not computable until grant.Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Mar 2041 · High confidence
Also notable
Ends Jan 2041 · High confidence
Also notable
Ends no later than Mar 2042 · Medium confidence
System and Method for Patient Monitoring of Gastrointestinal Function Using Automated Stool Classifications
US 11,532,396
The most cited patent in this portfolio, cited by 11 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2041.
18-MC for Treatment of Substance Use Disorders
US 11,596,638
Granted 2023. Computed term ends 2041.
Formulations of Psilocin That Have Enhanced Stability
US 12,097,184
A family of 6 related applications built on the 2024 grant. Too new for citation comparison; protection runs to 2042. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 13, 2027The maintenance fee for Synthesis Routes to Access Mdma Prodrugs by Using Controlled and Non-Controlled Intermediates (US 11,896,670) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 7 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS | 3 in force | to Aug 2042 |
| LSD Salt Crystal Forms | 1 in force | to Apr 2043 |
| Synthesis Routes to Access Mdma Prodrugs by Using Controlled and Non-Controlled Intermediates | 1 in force | to Aug 2042 |
| Movement Disorders | 1 in force | to May 2042 |
| Formulations of Psilocin That Have Enhanced Stability | 1 in force | to Mar 2042 |
| 18-MC for Treatment of Substance Use Disorders | 1 in force | to Jan 2041 |
Patents held now
Soonest term end first.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,596,638 | 18-MC for Treatment of Substance Use Disorders In force · High confidence | In force | High confidence | |
| US 11,532,396 | System and Method for Patient Monitoring of Gastrointestinal Function Using Automated Stool Classifications In force · High confidence | In force | High confidence | |
| US 12,097,184 | Formulations of Psilocin That Have Enhanced Stability In force · Medium confidence | In force | Medium confidence | |
| US 12,611,399 | Movement Disorders In force · High confidence | In force | High confidence | |
| US 12,036,220 | LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS In force · High confidence | In force | High confidence | |
| US 12,521,385 | LYOPHILIZED ORALLY DISINTEGRATING TABLET FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS In force · Medium confidence | In force | Medium confidence | |
| US 12,527,786 | IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS In force · Medium confidence | In force | Medium confidence | |
| US 11,896,670 | Synthesis Routes to Access Mdma Prodrugs by Using Controlled and Non-Controlled Intermediates In force · High confidence | In force | High confidence | |
| US 12,534,460 | LSD Salt Crystal Forms In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 17 applications pending · 24 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.